Table 1 Magnitude of complement-fixing antibodies against merozoite antigens

From: Targets of complement-fixing antibodies in protective immunity against malaria in children

Antigen

Age

Enrolment P. falciparum parasitemic status

<9 yrs na

≥9 yrs na

P c

PCR- na

PCR+ na

P b

Merozoites

0.24 [0.14–0.33]

0.35 [0.26–0.43]

<0.0001

0.23 [0.08–0.34]

0.34 [0.23–0.43]

<0.0001

MSP1–19

0.26 [0.19–0.42]

0.29 [0.19–0.51]

0.3

0.23 [0.17–0.37]

0.29 [0.2–0.49]

0.05

MSP1–42

0.15 [0.04–0.42]

0.29 [0.11–0.6]

0.007

0.11 [0.02–0.33]

0.32 [0.12–0.57]

<0.0001

MSP2 (3D7)

0.1 [0.04–0.21]

0.164 [0.09–0.28]

0.003

0.07 [0.03–0.17]

0.17 [0.09–0.28]

<0.0001

MSP2 (FC27)

0.04 [0.009–0.15]

0.09 [0.02–0.47]

0.03

0.02 [0.001–0.1]

0.1 [0.02–0.42]

<0.0001

MSP3

0.24 [0.17–0.35]

0.22 [0.15–0.34]

0.2

0.19 [0.12–0.25]

0.25 [0.18–0.37]

0.0004

MSP4

0.14 [0.05–0.35]

0.22 [0.12–0.48]

0.007

0.1 [0.04–0.19]

0.25 [0.12–0.57]

<0.0001

MSP6

0.17 [0.11–0.42]

0.24 [0.13–0.52]

0.19

0.14 [0.08–0.27]

0.25 [0.14–0.52]

0.0003

MSP7

0.34 [0.17–0.58]

0.42 [0.22–0.68]

0.08

0.23 [0.11–0.46]

0.44 [0.28–0.75]

<0.0001

MSP9

0.08 [0.06–0.14]

0.17 [0.08–0.35]

<0.0001

0.07 [0.05–0.13]

0.16 [0.09–0.33]

<0.0001

MSP10

0.25 [0.13–0.42]

0.29 [0.16–0.54]

0.2

0.18 [0.11–0.32]

0.31 [0.18–0.54]

0.0001

MSP-DBL1

0.44 [0.1–1.06]

0.62 [0.21–1.37]

0.05

0.22 [0.07–0.94]

0.65 [0.26–1.27]

0.003

Ripr

0.34 [0.23–0.46]

0.31 [0.2–0.56]

0.86

0.26 [0.18–0.48]

0.33 [0.24–0.53]

0.03

GAMA

0.27 [0.16–0.57]

0.43 [0.29–0.59]

0.006

0.25 [0.13–0.45]

0.44 [0.27–0.61]

<0.0001

RALP1

0.15 [0.08–0.36]

0.38 [0.18–0.66]

<0.0001

0.16 [0.09–0.33]

0.33 [0.15–0.6]

0.0002

AMA1

0.26 [0.08–0.82]

0.38 [0.18–0.78]

0.056

0.16 [0.04–0.47]

0.48 [0.22–0.96]

<0.0001

EBA140 RII

0.89 [0.44–1.25]

1.05 [0.65–1.36]

0.02

0.85 [0.29–1.3]

1.03 [0.69–1.32]

0.08

EBA140 RIII-V

0.1 [0.05–0.26]

0.18 [0.08–0.39]

0.01

0.09 [0.05–0.2]

0.19 [0.09–0.46]

<0.0001

EBA175RIII-V

0.14 [0.07–0.30]

0.26 [0.14–0.64]

0.0006

0.12 [0.07–0.26]

0.25 [0.13–0.66]

<0.0001

EBA175RII

0.70 [0.08–1.33]

1.04 [0.28–1.43]

0.013

0.28 [0.04–0.85]

1.12 [0.33–1.43]

<0.0001

Rh2–2030

0.26 [0.1–0.49]

0.3 [0.14–0.50]

0.22

0.16 [0.08–0.38]

0.31 [0.17–0.56]

0.0001

PfRh5

0.19 [0.15–0.29]

0.26 [0.17–0.41]

0.01

0.17 [0.12–0.26]

0.25 [0.17–0.38]

0.0004

Pf113

0.07 [0.04–0.12]

0.1 [0.06–0.17]

0.03

0.06 [0.03–0.12]

0.09 [0.05–0.16]

0.008

  1. Median optical density [OD] and interquartile range [IQR] are displayed. The 3D7 reference strain was used for all antigens; the FC27 strain was also assessed for MSP2
  2. aNumbers (n) analysed (n < 9 yrs, n ≥ 9 yrs, n PCR-, n PCR+) are as follows: 87, 109, 64, 132 for MSPDBL1, MSP7, GAMA, RALP1; 87, 110, 64, 133 for MSP6, EBA140RII, EBA140RIII-V, Rh5; 88, 110, 64, 133 for MSP1–42, EBA175RIII-V; 90, 110, 65, 135 for Merozoites, MSP1–19, EBA175RII, MSP2 (3D7 and FC27); 90, 111, 65, 136 for MSP4, AMA1; 90, 114, 65, 139 for Ripr; RH2–2030: 88, 110, 64, 134; MSP9: 84, 109, 63, 130; MSP10: 88, 104, 62, 130; Pf113: 85, 94, 58, 121
  3. b,cp indicates statistical significance (Wilcoxon rank-sum tests)
Back to article page